Status:
TERMINATED
Prevention of Cardiovascular Complications in Diabetic Patients With Vitamin E Treatment
Lead Sponsor:
Technion, Israel Institute of Technology
Collaborating Sponsors:
Clalit Health Services
The Kennedy Leigh Charitable Trust
Conditions:
Diabetes
Myocardial Infarction
Eligibility:
All Genders
55+ years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to determine whether Vitamin E treatment to Diabetic patients, who carry the Haptoglobin 2-2 Phenotype, prevents cardiovascular complications such as acute MI and Stroke.
Detailed Description
Haptoglobin is a free Hemoglobin scavenger protein. Hemoglobin is an oxidant due to the Fe it carries by the Fenton reaction. Thus it is believed that Haptoglobin is an antioxidant, especially in the ...
Eligibility Criteria
Inclusion
- Diabetic patients aged 55 and above
Exclusion
- Patient who takes antioxidant treatment will be asked to stop, or can't be included in the study
- Patients who had a CVD incident (MI, Stroke, TIA), Unstable angina pectoris, Uncontrolled HTN, will have to wait a month after stabilization to be included in the study
- Allergy to Vitamin E
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
End Date :
December 1 2009
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT00220831
Start Date
April 1 2005
End Date
December 1 2009
Last Update
March 1 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clalit Health Services, Haifa and West Galilee - primary health care clinics, in the north of Israel And the Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Haifa, Israel